Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers

Not Applicable

Completed

Conditions: Lower Extremity Ulcer
Venous Insufficiency
Venous Reflux

Interventions: Device: MIST Therapy

Registration Number: NCT01549860

Lead Sponsor: Celleration, Inc.

Brief Summary: This trial is a prospective, randomized, controlled, multi-center study of subjects presenting with chronic lower extremity venous ulcers. The study will evaluate the safety and effectiveness of MIST Therapy® plus standard of care (MIST+SOC) compared to Standard of Care (SOC) alone in the treatment of lower extremity venous ulcers.

Detailed Description: The study compared the treatment effect of non-contact low frequency ultrasound in addition to standard of care versus standard of care alone in healing chronic venous leg ulcers in subjects who had documented venous stasis and reflux. Subjects that were screened and met the major inclusion criteria received standardized treatment of 30 to 40 mmHg compression, moist wound healing dressings, and debridement for a two week run-in period. If their study ulcer did not decreased by greater than 30% they were eligible for randomization. The primary endpoint was wound area reduction after four (4) weeks of study treatment. The study was performed at 22 study centers. The study included two sub-studies: fluid and tissue analysis and a wound recidivism registry that are ongoing.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 156

Inclusion Criteria

Lower extremity full thickness venous ulcer of > 30 days duration
Subject's wound must be between 4 cm² and 50 cm² at screening
Documented ABI that is between 0.8 and 1.2 on the study limb or transcutaneous partial pressure oxygen (TcpO2) > 40 mmHG; or a toe pressure > 40 mmHG; or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic waveforms) at time of screening
Biopsy for wounds > 6 months duration
Documented index wound etiology of venous stasis with reflux and /or incompetent valves

Exclusion Criteria

Index ulcer wound that is less than 1 cm in distance from another ulcer wound
> 5 ulcers on the index leg
Index ulcer wound has exposed tendons, ligaments, muscle, or bone
Index ulcer wound presents with clinical signs of acute infection, suspected or known
Subjects with evidence of osteomyelitis or cellulitis or gangrene in the study limb
Subjects with amputation above a Trans Metatarsal Amputation (TMA) in the study limb
Subjects with active malignancy on the study limb except non-melanoma skin cancer
Index ulcer that is of arterial disease etiology
Index ulcer of other primary etiology (ie. vasculitis, arterial, pyoderma)
Subjects with planned vascular surgery, angioplasty or thrombolysis procedures within the study treatment phase
Subjects with planned surgical procedure during the study treatment phase for the index wound including skin flap or skin graft
Subjects within 6 weeks postoperatively of a vascular o skin graft procedure.
Subject has had prior skin replacement, negative pressure therapy, or traditional ultrasound therapy applied to the index wound in the 14 days prior to screening
Subject has had ultrasound treatment (including MIST Therapy) of the index wound.
Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within 14 days of screening date.
Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
Female subjects that are pregnant or refuse to utilize adequate contraceptive methods and are of childbearing age during the trial.
Subject has one or more medical condition(s), uncontrolled diabetes (i.e. HbA1c > 12), renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the subject an inappropriate study candidate
Subject's wound would require ultrasound near an electronic implant or prosthesis
Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements
Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SOC + Mist Therapy	MIST Therapy	30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Wound Area Mean Percent Reduction	4 weeks post baseline visit (randomization visit)	Compare between the treatment groups percent wound area reduction at four weeks of study treatment. H0: µMIST+SC -- µSC = 0 HA: µMIST+SC -- µSC ≠ 0 Where µ = percent reduction in wound size.

Secondary Outcome Measures

Name	Time	Method
Change in Pain VAS Scores	Baseline, 2 weeks and 4 weeks post randomization	Compare VAS Pain Scores between arms at baseline and 4 weeks post randomization Subjects indicate their pain level by drawing a mark on a 10 cm line on a visual analog scale (VAS) at randomization and 4 week post treatment visit. The left end of the line indicates "no pain" and the right end of line indicates "worst pain imaginable". VAS score is determined by using a ruler placed at 0 (left end of scale) and measuring the distance from zero to the patient's mark . The objective is to compare the change in VAS values in MIST+SC to SC alone. H0: The average change in pain level is not different between MIST and SC HA: The average change in pain level is different between MIST and SC H0: µMIST = µSC vs HA: µMIST ≠ µSC, Statistical Analysis. A repeated measures ANCOVA will be used to test for differences in change in VAS with an indicator variable to indicate treatment, any demographic variables which were significant in the baseline comparisons.
Heal Rates	12 weeks post randomization	Compare rate of wound closure between study arms for 12 weeks post randomization. Descriptive statistics as not a powered endpoint.